Race Oncology CSO Dr Daniel Tillett discusses the bright future for Zantrene Posted on August 29th, 2022 . Updated on May 9th, 2023 by Paul LangleyWe speak with Dr Daniel Tillett, Chief Scientific Officer of Race Oncology, about the potential market and efficacy of their drug, Zantrene, which seems likely to change the cancer treatment landscape in the near future.